Pazopanib: An oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma

Annals of Pharmacotherapy

Volumn 44, Issue 6, 2010, Pages 1054-1060

  LaPlant, Kourtney D ^a,b   Louzon, Paige D ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

GW786034; Pazopanib; Renal cell carcinoma; Tyrosine kinase inhibitors; Votrient

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 3A4; CYTOKINE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; KETOCONAZOLE; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RITONAVIR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VOTRIENT;

ABNORMAL LABORATORY RESULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CLINICAL TRIAL; DEPIGMENTATION; DIARRHEA; DRUG ACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; HAIR DISCOLORATION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; NAUSEA; NEUTROPENIA; OVARY CANCER; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SULFONAMIDES;

EID: 77952928989     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M251     Document Type: Review

References (36)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorgenesis. Cell 1996;86:353-364 (Pubitemid 26272076)
3. Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007;9:115-119 (Pubitemid 46332383)
4. Michaelson MD. ASCO 2006 highlights: targeted therapy for renal cell carcinoma. Cancer Treat Rev 2007;33:381-390
5. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A 1996;93:10589-10594 (Pubitemid 26333031)
6. Hutson TE. Targeted therapy for renal cell carcinoma: a new treatment paradigm. Proc (Bayl Univ Med Cent) 2007;20:244-248
7. Goodsell DS. The molecular perspective: VEGF and angiogenesis. Stem Cells 2003;21:118-119
8. Kumar R, Rudolph SK, Crosby RM, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:201-221 (Pubitemid 47052491)
9. The NCCN Clinical Practice Guidelines in Oncology Kidney Cancer (version 2.2010). 2009 National Comprehensive Cancer Network, Inc. www.NCCN.org (accessed 2010 Jan 1).
10. Kerbel RS. Molecular origins of cancer: tumor angiogenesis. N Engl J Med 2008;358:2039-2049
11. Podar K, Anderson KC. Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies. Cell Cycle 2007;6:538-542 (Pubitemid 46440425)
12. Prescribing information. Votrient (pazopanib). Research Traingle Park, NC: GlaxoSmithKline, October 2009.
13. Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Inves Drugs 2008;9:1324-1335
14. Hicklin DJ, Ellis LM. Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-1027 (Pubitemid 46202320)
15. Sonpavde G, Hutson TE, Sternberg CN. Pazopanib, a potent orally administered small molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Invest Drugs 2008;17:253-261 (Pubitemid 351578205)
16. Hurwitz H, Dowlati A, Savage S, et al. Safety, tolerability, and pharmacokinetics of oral administration of GW780634 in pts with solid tumors. J Clin Oncol 2005;(suppl 16S):3012.
17. Hutson TE, Davis ID, Machiels JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT) (abstract 5031). J Clin Oncol 2007;25(suppl):18S.
18. Hutson TE, Bukowski RM. A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear cell renal cell carcinoma. Clin Genitourin Cancer 2006;4: 296-298
19. Hutson TE, Davis ID, Machiels JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol. ASCO Annual Meeting Proceedings Part 1 2007;25(18S):5031.
20. Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28:475-480
21. Sternberg CN, Szczylik C, Lee E, et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) (abstract 5021). J Clin Oncol 2009;27(suppl):27.
22. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;6:1061-1068
23. Hawkins RE, Hong SJ, Ulys A, et al. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC) (abstract 5110). J Clin Oncol 2009;27(suppl):27.
24. GlaxoSmithKline. NCT00720941: Study VEG108844, a study of pazopanib versus sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma. www.clinicaltrials.gov (accessed 2010 Jan 1).
25. Slamon D, Gomez HL, Kabbinavar FF, et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer (abstract 1016). J Clin Oncol 2008; 26(suppl).
26. Altorki N, Guarino M, Lee P, et al. Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in earlystage non-small cell lung cancer (NSCLC): a proof-of-concept phase II study (abstract 7557). J Clin Oncol 2008;26(suppl).
27. Sleijfer S, Ray-Coquard I, Papai Z, et al. Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043 (abstract 10031). J Clin Oncol 2007;25(suppl):18S.
28. Intergroupe Francophone de Cancerologie Thoracique. NCT00775307: A randomized, double-blind, placebo-controlled phase II-III multi-centre study to evaluate the effect of adjuvant pazopanib (GW786034) versus placebo on post-surgical disease-free survival in patients with stage I non small cell lung cancer and tumor size equal or inferior to 5 cm. www. clinicaltrials.gov (accessed 2009 Apr 28).
29. Friedlander M, Hancock KC, Benigno B, et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a phase II study (abstract 5561). J Clin Oncol 2007;25(suppl):18S.
30. GlaxoSmithKline. NCT00866697: a phase III study to evaluate the efficacy and safety of pazopanib monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer. www.clinicaltrials.gov (accessed 2010 Jan 1).
31. European Organization for Research and Treatment of Cancer. NCT00794521: a randomized double blind phase III trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy. www.clinicaltrials.gov (accessed 2010 Jan 1).
32. Routhouska S, Gilliam AC, Mirmirani P. Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor. Arch Dermatol 2006;142:1477-1479 (Pubitemid 44790642)
33. Suttle B, Jones S, Dowlati A, Tan A, et al. Phase I study of the safety and pharmacokinetics (PK) of paclitaxel or paclitaxel with carboplatin administered in combination with pazopanib (GW786034) (abstract 14118). ASCO Annu Meeting Proc Part 1. 2007;25(suppl):18S.
34. Red book. 2009 ed. Montvale, NJ: Thomson Healthcare Inc., 2009.
35. Product information. Nexavar (sorafenib). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., February 2009.
36. Product information. Sutent (sunitinib). New York, NY: Pfizer, July 2009.